Masimo’s preliminary proxy statement has now formally initiated the proposed acquisition of Danaher. The filing requests shareholders' approval of Danaher’s $180 (€166) per-share cash purchase of Masimo, valuing the deal at approximately $9.9 billion (€9.1 billion), including debt.
Masimo’s board has unanimously approved the deal and recommends that shareholders vote in favour at a virtual special meeting, while activist investor Politan Capital has signed a voting and support agreement committing its shares to endorse the transaction. If completed, Masimo will become a wholly owned subsidiary of Danaher and will be delisted from Nasdaq.
On one level, this is a typical medtech M&A story: a premium cash exit, a fairness opinion, a shareholder vote, regulatory approvals, and a termination fee of $305 million (€281 million) under certain circumstances. But the more significant message is strategic. This transaction is less about ownership of a monitoring company than about gaining control of one of healthcare’s most valuable assets: continuous clinical data generated at the bedside.
The proxy clearly explains the mechanics. Shareholders are asked to approve two items: firstly, the merger agreement itself, which requires approval by holders of a majority of the outstanding shares entitled to vote; and secondly, a non-binding advisory vote on merger-related executive compensation. Masimo’s filing also details what happens to options, RSUs, and PSUs, the treatment of employee benefits and indemnification, and the appraisal rights available to dissenting shareholders under Delaware law. In simple terms, this is the legal and governance framework for Masimo’s exit as an independent public company.
What makes the transaction more consequential is why Danaher is interested in Masimo now. Danaher stated in its acquisition announcement that Masimo is a “leading specialty diagnostics provider of pulse oximetry and other patient monitoring solutions, primarily in acute care settings,” and that the deal is expected to strengthen Danaher’s diagnostics segment. Danaher also said it expects the transaction to close in the second half of 2026, subject to shareholder and regulatory approvals.
That positioning matters. Danaher already has strong expertise in diagnostics and life sciences through companies like Beckman Coulter, Cepheid, and Radiometer. What it has lacked is a robust proprietary position in continuous bedside monitoring. Masimo fills that gap. It brings a clinically proven monitoring franchise, a substantial installed base, and a high-value stream of real-time physiological data. Strategically, this means Danaher is moving closer to the clinical decision layer within hospitals: the stage where signals are captured, interpreted, and increasingly linked to intervention.
This is why the deal should not be seen solely as a bet on pulse oximetry; it is a bet on integration. Diagnostics offer episodic insights, while monitoring provides continuous visibility. Combining the two shifts the focus from device ownership to pathway management—enabling earlier detection, faster escalation, and closer integration between monitoring and diagnostics, ultimately supporting AI-enabled clinical decision-making.
The transaction also reveals a lot about Masimo itself. Masimo entered 2026 in a stronger operational position than during the turbulence of the previous few years. In January, the company announced preliminary fourth-quarter 2025 revenue of about $411 million (€379 million), up approximately 12%, and full-year 2025 revenue of around $1.51 billion (€1.39 billion), up approximately 10%. However, the board still decided that a complete cash sale was better than the risks of remaining independent.
The voting agreement with Politan is especially revealing. It shows that the board and its most vocal activist shareholder agree: securing value now is better than continuing the independent path with its inherent execution, governance, and market risks.
What implications does this have for the competitors?
GE HealthCare now faces a stronger challenger in acute care. Historically, Masimo technology has often operated alongside broader monitoring systems rather than being directed by a diagnostics-led owner. Under Danaher, that shifts. GE will need to defend not only its installed base and workflow integration but also the strategic rationale for aligning monitoring with imaging and enterprise platforms instead of diagnostics. The question is how far GE will push this positioning in response.
Philips faces a different pressure. Its longstanding strength in monitoring and connected care has depended on the integration of devices, central monitoring, and informatics. With the rise of plug-and-play systems from competitors such as Mindray, it is already facing pressure in key markets. Danaher–Masimo introduces a competitor with a sharper focus on measurement quality and acute-care integration, likely pushing Philips further towards informatics, workflow orchestration and enterprise partnerships.
Medtronic is affected in more specific ways. With Nellcor and its broader respiratory and monitoring footprint, it competes more directly in sensing and physiological surveillance. A Danaher-backed Masimo is a stronger long-term competitor, not only because of its capital strength but also because Danaher can link sensors to a broader diagnostics-and-analytics narrative.
Mindray presents a different but increasingly important force in the ICU market. With a dominant position in China and a rapidly growing global presence, Mindray is gaining ground in intensive care by offering fully integrated monitoring, ventilation and patient management systems at highly competitive price points.
While Western companies focus on high-end, data-driven platforms, Mindray is capturing market share through scalable, cost-effective ICU solutions—particularly in emerging markets and increasingly in mid-tier hospitals across Europe and beyond.
As ICU demand rises and budget pressures intensify, a two-speed market is emerging: premium, integrated ecosystems led by Danaher, GE HealthCare and Philips, and high-value, system-level alternatives led by Mindray.
This shift is not just increasing competition—it is fundamentally transforming how ICU technology is evaluated, procured and implemented. The market is shifting towards platforms that integrate signals, diagnostics, software, and workflow. In this setting, standalone monitoring businesses become strategically vulnerable, as scale, integration, and data ownership start to outweigh device performance alone.
Impact and Challenge
For healthcare leaders, this has immediate practical implications. Procurement teams should expect future bids in monitoring and diagnostics to become more integrated. CIOs and CMIOs must scrutinise interoperability, data access and governance with increased diligence, as vendor selection increasingly influences not only equipment fleets but also clinical frameworks.
Boards should recognise that the next phase of competition will focus less on hardware refresh cycles and more on controlling the data layer that supports early warning systems, escalation processes, and clinical workflow redesign.
Masimo’s proxy statement may be a voting document, but strategically, it signals that the era of standalone monitoring is coming to an end. The companies that succeed in the next phase of acute care will not merely produce superior devices—they will control the systems that link continuous signals to decisions, diagnostics and outcomes.
Danaher has understood this clearly. The question now is which platform will shape clinical decision-making in your organisation.
Image Credit: iStock
